Votrient (pazopanib) / Novartis, BeiGene  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Votrient (pazopanib) / Novartis, BeiGene
NCT02354612: Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

No Longer Available
N/A
US
TRC105, Chimeric Antibody (TRC105) to CD105, Bevacizumab, Avastin, Axitinib, Inlyta, Pazopanib, Votrient, Capecitabine, Xeloda
Tracon Pharmaceuticals Inc.
Solid Tumors
 
 
COMBOREIN, NCT03571438: Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors

Recruiting
N/A
100
Europe
CK2 and ATM inhibitors serine/ threonin Kinase combination, Sunitinib, Pazopanib, Temsirolimus
University Hospital, Grenoble
Kidney Cancer
09/22
09/24
NCT05816642: Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Recruiting
N/A
500
RoW
sunitinib or pazopanib, PD-1 inhibitor combined with axitinib
RenJi Hospital, Ruijin Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, West China Hospital, Xiangya Hospital of Central South University, Fudan University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Second Affiliated Hospital of Nantong University, Peking University First Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The General Hospital of Eastern Theater Command, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of University of Science and Technology of China, The Second Hospital of Anhui Medical University, Tongji Hospital, The First Affiliated Hospital of Zhengzhou University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, Changzhi Medical College, First Affiliated Hospital Xi'an Jiaotong University, Second Affiliated Hospital of Xi'an Jiaotong University, Xijing Hospital of Air Force Military Medical University, Tang-Du Hospital, Quanzhou First Hospital Affiliated to Fujian Medical University, Third Affiliated Hospital, Sun Yat-Sen University
Metastatic Renal Cell Carcinoma
12/23
12/24
ChiCTR1900026199: Efficacy and safety of neoadjuvant therapy with pazopanib plus PD-1 antibodies in renal cell carcinoma that having indication of partial nephrectomy but in high surgical risk: a single arm and phase II clinical trial

Recruiting
N/A
29
 
Neoadjuvant therapy with pazopanib plus PD-1 antibodies
Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, None
renal cancer
 
 

Download Options